You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

301 Results
Guidelines and Advice
Status: Archived
ID: 2-22
Sep 2011
Guidelines and Advice
Status: Archived
ID: 3-8-2
Version: 2
Sep 2011
Guidelines and Advice
Status: Archived
ID: 8-3
Sep 2011
Guidelines and Advice
Status: Archived
ID: 8-4
Sep 2011
Guidelines and Advice
Status: Archived
ID: 8-5
Version: 2
Sep 2011
Guidelines and Advice
Status: Archived
ID: 11-4
Sep 2011
Guidelines and Advice
Status: Archived
ID: 11-5
Sep 2011
Guidelines and Advice
Status: Archived
ID: 1-15 Version 3
Version: 3
Sep 2011
Drug
Other Name(s): AMSA P D® (Erfa)
Quick Link(s):
Drug Monograph
Sep 2011
Drug
Other Name(s): Lynparza®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capivasertib (Unfunded),
fulvestrant
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enfortumab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025

Pages